News Releases
-
Tablet Development Process Training - July 20-21
This course provides comprehensive insight into the tablet development process to provide powerful tools that you can put to work immediately.Released by: Federal Equipment Company
-
Promotions & Moves
Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer
He succeeds Walter J. Kaczmarek III, who is stepping down as Chief Executive Officer.Released by: Alcami
-
Humanigen & Emergent Biosolutions Announce Agreement for Phase 3 Covid-19 Therapeutic Candidate
Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.Released by: Emergent BioSolutions
-
Vetter continues its successful performance at the 2021 CMO Leadership Awards
Winning five core categories reaffirms Vetter as a trusted solution provider, particularly during globally challenging times.Released by: Vetter Pharma International
-
-
Vetter continues to implement its long-term sustainability strategy
Minister of Transport praises the commitment of the pharmaceutical service provider during global turbulent timesReleased by: Vetter Pharma International
-
Syngene and Deerfield Discovery and Development (3DC) sign 5-year strategic collaboration
...Released by: Syngene
-
CCRM and McMaster Innovation Park (MIP) Partner to Build and Operate Biomanufacturing Campus
...Released by: CCRM
-
-
Syngene International Q2 profit up 64 pc to Rs 128 cr
Press Trust of India | New DelhiReleased by: Syngene
-
Vetter continues its long-term investment strategy to sustain future growth
Existing buildings are repurposed as others continue to be built and recently housedReleased by: Vetter Pharma International
-
Syngene joins global consortium to accelerate research in COVID-19 testing
The consortium brings together a diverse group of companies with synergistic areas of expertiseReleased by: Syngene
-
-
Kohlberg and Mubadala sign a definitive agreement to acquire majority stake in PCI Pharma Services
...Released by: PCI Pharma Services
-
A strong signal in turbulent times: Vetter achieves carbon dioxide-neutral levels
Contract Development and Manufacturing Organization further expands its commitment to climate protectionReleased by: Vetter Pharma International
-
PCI Pharma Services Announces Global Expansion of Clinical Trial Services
PCI Broadens Global Clinical Supply-Chain Service Offerings Into Mainland EuropeReleased by: PCI Pharma Services
-
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration
to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense FundingReleased by: Emergent BioSolutions
-
Vetter further expands its Development Service with new site in Austria
With the new Vetter Development Service Rankweil site in Austria, Vetter expands its European footprint.Released by: Vetter Pharma International
-
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing
for Johnson & Johnson’s Lead COVID-19 Vaccine CandidateReleased by: Emergent BioSolutions
-
The key to tackling drug development complexity: Collaboration.
Rentschler Biopharma and Vetter team up with joint goal to simplify processes and optimize time-to-marketReleased by: Vetter Pharma International
